Neuroimaging of toxic and metabolic disorders

Seminars in Neurology

Volumn 28, Issue 4, 2008, Pages 495-510

  Arora, Ashish ^a   Neema, Mohit ^a   Stankiewicz, James ^a   Guss, Zachary D ^a   Guss, Jason G ^a   Prockop, Leon ^c   Bakshi, Rohit ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain; Metabolic disorders; MRI; Neurotoxicity; Toxin exposure

Indexed keywords

CARBON MONOXIDE; COCAINE; CYCLOSPORIN; CYTARABINE; DIAMORPHINE; FLUOROURACIL; LEVAMISOLE; MANGANESE; METHAMPHETAMINE; METHANOL; METHOTREXATE; TACROLIMUS; TOLUENE;

ACERULOPLASMINEMIA; ALCOHOLISM; BRAIN TOXICITY; CARBON MONOXIDE INTOXICATION; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; EPILEPSY; HUMAN; KEARNS SAYRE SYNDROME; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; LEUKOENCEPHALOPATHY; LIVER FAILURE; MALNUTRITION; METABOLIC DISORDER; MITOCHONDRIAL ENCEPHALOPATHY; MYOCLONUS; NERVE DEGENERATION; NEUROFERRITINOPATHY; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSMOTIC DEMYELINATION SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION NECROSIS; REVIEW; SIDEROSIS; WERNICKE ENCEPHALOPATHY; WILSON DISEASE;

BRAIN MAPPING; DIAGNOSTIC IMAGING; HUMANS; METABOLIC DISEASES; NEUROTOXICITY SYNDROMES;

EID: 56049123459     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0028-1083684     Document Type: Review

References (167)

1. Crépat G, Fritsch R. Carbon monoxide: the unnoticed poison of the 21st century. Proceedings of the Satellite Meeting IUTOX VIIIth International Congress of Toxicology; July 3-4, 1998; Université de Bourgogne, Dijon, France
2. Ernst A, Zibrak J. Carbon monoxide poisoning. N Engl J Med 1998;339:1603-1608
3. Bour H, Tutin M, Pasquier P. The central nervous system and carbon monoxide poisoning: clinical data with reference to 20 fatal cases. Prog Brain Res 1967;24:1-30
4. Okazaki H. Fundamentals of Neuropathology. Tokyo: Agaku-Shoin; 1989
5. Schils F, Cabay JE, Flandroy P, Dondelinger RF. Unusual CT and MRI appearance of carbon monoxide poisoning. JBR-BTR 1999;82:13-15
6. Prockop LD. Carbon monoxide brain toxicity: clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people. J Neuroimaging 2005;15:144-149
7. Murata T, Kimura H, Kado H, et al. Neuronal damage in the interval form of CO poisoning determined by serial diffusion weighted magnetic resonance imaging plus 1H-magnetic resonance spectroscopy. J Neurol Neurosurg Psychiatry 2001;71:250-253
8. Sener RN. Acute carbon monoxide poisoning: diffusion MR imaging findings. AJNR Am J Neuroradiol 2003;24:1475-1477
9. Lo CP, Chen SY, Chou MC, et al. Diffusion-tensor MR imaging for evaluation of the efficacy of hyperbaric oxygen therapy in patients with delayed neuropsychiatric syndrome caused by carbon monoxide inhalation. Eur J Neurol 2007;14:777-782
10. Prockop LD, Chichkova RI. Carbon monoxide intoxication: an updated review. J Neurol Sci 2007;262:122-130
11. Scroop R, Sage MR, Voyvodic F, Kat E. Radiographic imaging procedures in the diagnosis of the major central neuropathological consequences of alcohol abuse. Australas Radiol 2002;46:146-153
12. Heinrich A, Runge U, Khaw AV. Clinicoradiologic subtypes of Marchiafava-Bignami disease. J Neurol 2004;251:1050-1059
13. Kohler CG, Ances BM, Coleman AR, Ragland JD, Lazarev M, Gur RC. Marchiafava-Bignami disease: literature review and case report. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:67-76
14. Lavin PJ, Smith D, Kori SH, Ellenberger C Jr. Wernicke's encephalopathy: a predictable complication of hyperemesis gravidarum. Obstet Gynecol 1983;62:13s-15s
15. Nightingale S, Bates D, Heath PD, Barron SL. Wernicke's encephalopathy in hyperemesis gravidarum. Postgrad Med J 1982;58:558-559
16. Wood P, Murray A, Sinha B, Godley M, Goldsmith HJ. Wernicke's encephalopathy induced by hyperemesis gravidarum. Case reports. Br J Obstet Gynaecol 1983;90:583-586
17. Drenick EJ, Joven CB, Swendseid ME. Occurrence of acute Wernicke's encephalopathy during prolonged starvation for the treatment of obesity. N Engl J Med 1966;274:937-939
18. Lopez RI, Collins GH. Wernicke's encephalopathy. A complication of chronic hemodialysis. Arch Neurol 1968;18:248-259
19. Faris AA. Wernicke's encephalopathy in uremia. Neurology 1972;22:1293-1297
20. Park SH, Kim M, Na DL, Jeon BS. Magnetic resonance reflects the pathological evolution of Wernicke encephalopathy. J Neuroimaging 2001;11:406-411
21. D'Aprile P, Gentile MA, Carella A. Enhanced MR in the acute phase of Wernicke encephalopathy. AJNR Am J Neuroradiol 1994;15:591-593
22. Chu K, Kang DW, Kim HJ, Lee YS, Park SH. Diffusion-weighted imaging abnormalities in Wernicke encephalopathy: reversible cytotoxic edema? Arch Neurol 2002;59:123-127
23. Omer SM, al Kawi MZ, al Watban J, Bohlega S, McLean DR, Miller G. Acute Wernicke's encephalopathy associated with hyperemesis gravidarum: magnetic resonance imaging findings. J Neuroimaging 1995;5:251-253
24. Doss A, Mahad D, Romanowski CA. Wernicke encephalopathy: unusual findings in nonalcoholic patients. J Comput Assist Tomogr 2003;27:235-240
25. Jauhar P, Montaldi D. Wernicke-Korsakoff syndrome and the use of brain imaging. Alcohol Alcohol Suppl 2000;35:21-23
26. Lee S-T, Jung Y-M, Na DL, Park SH, Kim M. Corpus callosum atrophy in Wernicke's encephalopathy. J Neuroimaging 2005;15:367-372
27. Liu YT, Fuh JL, Lirng JF, Li AF, Ho DM, Wang SJ. Correlation of magnetic resonance images with neuropathology in acute Wernicke's encephalopathy. Clin Neurol Neurosurg 2006;108:682-687
28. Halavaara J, Brander A, Lyytinen J, Setala K, Kallela M. Wernicke's encephalopathy: is diffusion-weighted MRI useful? Neuroradiology 2003;45:519-523
29. Gaul HP, Wallace CJ, Auer RN, Fong TC. MR findings in methanol intoxication. AJNR Am J Neuroradiol 1995;16:1783-1786
30. Server A, Hovda KE, Nakstad PH, Jacobsen D, Dullerud R, Haakonsen M. Conventional and diffusion-weighted MRI in the evaluation of methanol poisoning. A case report. Acta Radiol 2003;44:691-695
31. Keles GT, Orgüç S, Toprak B, Ozaslan S, Sakarya M. Methanol poisoning with necrosis corpus callosum. Clin Toxicol (Phila) 2007;45:307-308
32. Kuteifan K, Oesterle H, Tajahmady T, Gutbub AM, Laplatte G. Necrosis and haemorrhage of the putamen in methanol poisoning shown on MRI. Neuroradiology 1998;40:158-160
33. Halavaara J, Valanne L, Setala K. Neuroimaging supports the clinical diagnosis of methanol poisoning. Neuroradiology 2002;44:924-928
34. Peters AS, Schwarze B, Tomandl B, Probst-Cousin S, Lang CJ, Hilz MJ. Bilateral striatal hyperintensities on diffusion weighted MRI in acute methanol poisoning. Eur J Neurol 2007;14:e1-e2
35. Watson JM. Solvent abuse: presentation and clinical diagnosis. Hum Toxicol 1982;1:249-256
36. Ashton CH. Solvent abuse. BMJ 1990;300:135-136
37. Gospe SM, Calaban MJ. Central nervous system distribution of inhaled toluene. Fundam Appl Toxicol 1988;11:540-545
38. Aydin K, Sencer S, Demir T, Ogel K, Tunaci A, Minareci O. Cranial MR findings in chronic toluene abuse by inhalation. AJNR Am J Neuroradiol 2002;23:1173-1179
39. Kamran S, Bakshi R. MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images. Neuroradiology 1998;40:519-521
40. Caldemeyer KS, Armstrong SW, George KK, Moran CC, Pascuzzi RM. The spectrum of neuroimaging abnormalities in solvent abuse and their clinical correlation. J Neuroimaging 1996;6:167-173
41. Aydin K, Sencer S, Ogel K, Genchellac H, Demir T, Minareci O. Single-voxel proton MR spectroscopy in toluene abuse. Magn Reson Imaging 2003;21:777-785
42. Caldemeyer KS, Pascuzzi RM, Moran CC, Smith RR. Toluene abuse causing reduced MR signal intensity in the brain. AJR Am J Roentgenol 1993;161:1259-1261
43. Unger E, Alexander A, Fritz T, Rosenberg N, Dreisbach J. Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted MR images. Radiology 1994;193:473-476
44. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-384
45. Marks JE, Baglan RJ, Prassad SC, Blank WF. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981;7:243-252
46. Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 1994;74:2828-2835
47. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol 1991;12:45-62
48. Rowley HA, Dillon WP. Iatrogenic white matter diseases. Neuroimag Clin N Am 1993;3:379-404
49. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. Radiology 1986;158:149-155
50. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201-209
51. Asao C, Korogi Y, Kitajima M, et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26:1455-1460
52. Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 2006;24:1131-1142
53. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-1867
54. Wang SX, Boethius J, Ericson K. FDG-PET on irradiated brain tumor: ten years' summary. Acta Radiol 2006;47:85-90
55. Tsuyuguchi N, Sunada I, Iwai Y, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-1064
56. Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005;185:1471-1476
57. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84:63-69
58. Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Physiol 2007;68:151-158
59. Bakshi R, Ketonen L. MRI of the brain in clinical neurology. In: Joynt RJ, Griggs RC, eds. Baker and Joynt's Clinical Neurology [book on CD-ROM]. Philadelphia, PA: Lippincott Williams & Wilkins; 2004
60. Bakshi R, Shaikh ZA, Bates VE, Kinkel PR. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 cases. Neurology 1999;52:1285-1288
61. Watanabe Y, Mitomo M, Tokuda Y, et al. Eclamptic encephalopathy: MRI, including diffusion-weighted images. Neuroradiology 2002;44:981-985
62. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500
63. Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporin neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627-631
64. Galassi G, Tassone G, Sintini M, Spagnoli M, Bertolani L, Mavilla L. 5-Fluorouracil- and levamisole-associated multifocal leukoencephalopathy. Eur Neurol 1996;36:244-246
65. Savarese DM, Gordon J, Smith TW, et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis - a case report. Cancer 1996;77:387-394
66. Honkaniemi J, Kähärä V, Dastidar P, et al. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology 2000;42:895-899
67. Furukawa M, Terae S, Chu BC, et al. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging. Neuroradiology 2001;43:615-621
68. Yamamoto A, Hayakawa K, Houjyou M. CT and MRI findings of cyclosporine-related encephalopathy and hypertensive encephalopathy. Pediatr Radiol 2002;32:340-343
69. Jarosz JM, Howlett DC, Cox TC, Bingham JB. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology 1997;39:711-715
70. Pace MT, Slovis TL, Kelly JK, Abella SD. Cyclosporin A toxicity: MRI appearance of the brain. Pediatr Radiol 1995;25:180-183
71. Goodman JM, Kuzma B. Encephalopathy following heart-lung transplantation. Surg Neurol 1996;46:157
72. Fisher NC, Ruban E, Carey M, Heafield MT, West RJ, Adams DH. Late-onset fatal acute leucoencephalopathy in liver transplant recipient. Lancet 1997;349:1884-1885
73. Kanekiyo T, Hara J, Matsuda-Hashii Y, et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol 2005;81:264-268
74. Israel ZH, Lossos A, Barak V, Soffer D, Siegal T. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncol 2000;39:117-120
75. Franco DA, Greenberg HS. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology 2001;56:110-112
76. Hook CC, Kimmell DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31:262-267
77. Ishibashi S, Nishimura H, Mizusawa H. 5-FU-induced acute leukoencephalopathy. Intern Med 2004;43:1009-1010
78. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981;48:2577-2582
79. Zawacki T, Friedman JH, Grace J, Shetty N. Cerebellar toxicity of cytosine arabinoside: clinical and neuropsychological signs. Neurology 2000;55:1234
80. Friedman JH, Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord 2001;16:575-577
81. Yeshurun M, Marsot Dupuch K. Acute cerebellar syndrome following intermediate-dose cytarabine. Br J Haematol 2001;113:846
82. Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003;60:326-328
83. Counsel P, Khangure M. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol 2007;62:172-176
84. Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol 2006;36:205-212
85. Ebner F, Ranner G, Slavc I, et al. MR findings in methotrexate-induced CNS abnormalities. AJR Am J Roentgenol 1989;153:1283-1288
86. Lien HH, Blomlie V, Saeter G, Solheim O, Fossa SD. Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 1991;179:547-550
87. Chu WC, Chik KW, Chan YL, et al. White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology 2003;229:659-669
88. Bartzokis G, Beckson M, Hance DB, et al. Magnetic resonance imaging evidence of "silent" cerebrovascular toxicity in cocaine dependence. Biol Psychiatry 1999;45:1203-1211
89. Lyoo IK, Streeter CC, Ahn KH, et al. White matter hyperintensities in subjects with cocaine and opiate dependence and healthy comparison subjects. Psychiatry Res 2004;131:135-145
90. He GQ, Zhang A, Altura BT, Altura BM. Cocaine-induced cerebrovasospasm and its possible mechanism of action. J Pharmacol Exp Ther 1994;268:1532-1539
91. Madden JA, Konkol RJ, Keller PA, Alvarez TA. Cocaine and benzoylecgonine constrict cerebral arteries by different mechanisms. Life Sci 1995;56:679-686
92. Andrews P. Cocaethylene toxicity. J Addict Dis 1997;16:75-84
93. Bartzokis G, Beckson M, Lu PH, et al. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res 2000;98:93-102
94. Moeller FG, Hasan KM, Steinberg JL, et al. Reduced anterior corpus callosum white matter integrity is related to increased impulsivity and reduced discriminability in cocaine-dependent subjects: diffusion tensor imaging. Neuropsychopharmacology 2005;30:610-617
95. Aron JL, Paulus MP. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction 2007;102(S1):33-43
96. Bae SC, Lyoo IK, Sung YH, et al. Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend 2006;81:83-88
97. Myers RE, Anderson LI, Dluzen DE. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 2003;44:624-632
98. Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005;162:1461-1472
99. Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 2005;57:967-974
100. Oh JS, Lyoo IK, Sung YH, et al. Shape changes of the corpus callosum in abstinent methamphetamine users. Neurosci Lett 2005;384:76-81
101. Sung YH, Cho SC, Hwang J, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend 2007;88:28-35
102. Hagel J, Andrews G, Vertinsky T, Heran MK, Keogh C. "Chasing the dragon"-imaging of heroin inhalation leukoencephalopathy. Can Assoc Radiol J 2005;56:199-203
103. Wolters EC, van Wijngaarden GK, Stam FC, et al. Leukoencephalopathy after inhaling "heroin" pyrolysate. Lancet 1982;2:1233-1237
104. Kriegstein AR, Shungu DC, Millar WS, Armitage BA, Brust JC, Chillrud S. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon"). Neurology 1999;53:1765-1773
105. Au-Yeung K, Lai C. Toxic leucoencephalopathy after heroin inhalation. Australas Radiol 2002;46:306-308
106. Keogh CF, Andrews GT, Spacey SD, Forkheim KE, Graeb DA. Neuroimaging features of heroin inhalation toxicity: "chasing the dragon." AJR Am J Roentgenol 2003;180:847-850
107. Weber W, Henkes H, Moller P, Bade K, Kuhne D. Toxic spongiform leucoencephalopathy after inhaling heroin vapour. Eur Radiol 1998;8:749-755
108. Tan TP, Algra PR, Valk J, Wolters EC. Toxic leukoencephalopathy after inhalation of poisoned heroin: MR findings. AJNR Am J Neuroradiol 1994;15:175-178
109. Fitsanakis VA, Zhang N, Avison M, Gore JC, Ashner JL, Ashner M. The use of MRI in the study of manganese neurotoxicity. Neurotoxicology 2006;27:798-806
110. Jiang Y, Zheng W, Long L, et al. Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers: search for biomarkers of manganese exposure. Neurotoxicology 2007;28:126-135
111. Pujol A, Graus F, Peri J, Mercader JM, Rimola A. Hyperintensity in the globus pallidus on T1-weighted and inversion-recovery MRI: a possible marker of advanced liver disease. Neurology 1991;41:1526-1527
112. Kulisevsky J, Pujol J, Balanzo J, et al. Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: clinical correlations. Hepatology 1992;16:1382-1388
113. Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993;43:65-69
114. Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-274
115. Ross BD, Jacobson S, Villamil F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457-463
116. Laubenberger J, Haussinger D, Bayer S, Gufler H, Hennig J, Langer M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997;112:1610-1616
117. Rovira A, Grive E, Pedraza S, Rovira A, Alonso J. Magnetization transfer ratio values and proton MR spectroscopy of normal-appearing cerebral white matter in patients with liver cirrhosis. AJNR Am J Neuroradiol 2001;22:1137-1142
118. Miese F, Kircheis G, Wittsack HJ, et al. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR Am J Neuroradiol 2006;27:1019-1026
119. Binesh N, Huda A, Thomas MA, et al. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological study. J Appl Clin Med Phys 2006;7:86-96
120. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481-488
121. Bianchi MC, Sgandurra G, Tosetti M, Battini R, Cioni G. Brain magnetic resonance in the diagnostic evaluation of mitochondrial encephalopathies. Biosci Rep 2007;27:69-85
122. Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 2006;20:443-464
123. Abe K, Yoshimura H, Tanaka H, Fujita N, Hikita T, Sakoda S. Comparison of conventional and diffusion-weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events. Neuroradiology 2004;46:113-117
124. Möller HE, Kurlemann G, Pützler M, Wiedermann D, Hilbich T, Fiedler B. Magnetic resonance spectroscopy in patients with MELAS. J Neurol Sci 2005;229-230:131-139
125. Oppenheim C, Galanaud D, Samson Y, et al. Can diffusion weighted magnetic resonance imaging help differentiate stroke from stroke-like events in MELAS? J Neurol Neurosurg Psychiatry 2000;69:248-250
126. Barragan-Campos HM, Vallee JN, Lo D, et al. Brain magnetic resonance imaging findings in patients with mitochondrial cytopathies. Arch Neurol 2005;62:737-742
127. Valanne L, Ketonen L, Majander A, Suomalainen A, Pihko H. Neuroradiologic findings in children with mitochondrial disorders. AJNR Am J Neuroradiol 1998;19:369-377
128. Chu BC, Terae S, Takahashi C, et al. MRI of the brain in the Kearns-Sayre syndrome: report of four cases and a review. Neuroradiology 1999;41:759-764
129. Harding AE, Sweeney MG, Miller DH, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979-989
130. Küker W, Weir A, Quaghebeur G, Palace J. White matter changes in Leber's hereditary optic neuropathy: MRI findings. Eur J Neurol 2007;14:591-593
131. Inglese M, Rovaris M, Bianchi S, et al. Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2001;70:444-449
132. Arii J, Tanabe Y. Leigh syndrome: serial MR imaging and clinical follow-up. AJNR Am J Neuroradiol 2000;21:1502-1509
133. Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006;114:217-238
134. Medina L, Chi TL, DeVivo DC, Hilal SK. MR findings in patients with subacute necrotizing encephalomyelopathy (Leigh disease): correlation with biochemical defect. AJNR Am J Neuroradiol 1990;11:379-384
135. Cooper MA, Fox R. Anesthesia for corrective spinal surgery in a patient with Leigh's disease. Anesth Analg 2003;97:1539-1541
136. Detre JA, Wang ZY, Bogdan AR, et al. Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol 1991;29:218-221
137. Takahashi S, Oki J, Miyamoto A, Okuno A. Proton magnetic resonance spectroscopy to study the metabolic changes in the brain of a patient with Leigh syndrome. Brain Dev 1999;21:200-204
138. Sakai Y, Kira R, Torisu H, Ihara K, Yoshiura T, Hara T. Persistent diffusion abnormalities in the brain stem of three children with mitochondrial diseases. AJNR Am J Neuroradiol 2006;27:1924-1926
139. Leutner C, Layer G, Zierz S, Solymosi L, Dewes W, Reiser M. Cerebral MR in ophthalmoplegia plus. AJNR Am J Neuroradiol 1994;15:681-687
140. Wray SH, Provenzale JM, Johns DR, Thulborn KR. MR of the brain in mitochondrial myopathy. AJNR Am J Neuroradiol 1995;16:1167-1173
141. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349
142. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40
143. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003;15:572-577
144. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988;24:692-694
145. Schaffert DA, Johnsen SD, Johnson PC, Drayer BP. Magnetic resonance imaging in pathologically proven Hallervorden-Spatz disease. Neurology 1989;39:440-442
146. Hayflick SJ, Penzien JM, Michl W, et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:166-169
147. Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006;27:1230-1233
148. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354
149. Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007;130:110-119
150. Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995;37:646-656
151. Grisoli M, Piperno A, Chiapparini L, Mariani R, Savoiardo M. MR imaging of cerebral cortical involvement in aceruloplasminemia. AJNR Am J Neuroradiol 2005;26:657-661
152. Kumar N, Cohen-Gadol AA, Wright RA, Miller GM, Piepgras DG, Ahlskog JE. Superficial siderosis. Neurology 2006;66:1144-1152
153. Offenbacher H, Fazekas F, Schmidt R, Kapeller P, Fazekas G. Superficial siderosis of the central nervous system: MRI findings and clinical significance. Neuroradiology 1996;38:S51-S56
154. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 1959;81:154-172
155. Tomlinson BE, Pierides AM, Bradley WG. Central pontine myelinolysis: two cases with associated electrolyte disturbance. Q J Med 1976;45:373-386
156. Newell KL, Kleinschmidt-Demasters BK. Central pontine myelinolysis at autopsy: a twelve-year retrospective analysis. J Neurol Sci 1996;142:134-139
157. Uchino A, Yuzuriha T, Murakami M, et al. Magnetic resonance imaging of sequelae of central pontine myelinolysis in chronic alcohol abusers. Neuroradiology 2003;45:877-880
158. Cramer SC, Stegbauer KC, Schneider A, Mukai J, Maravilla KR. Decreased diffusion in central pontine myelinolysis. AJNR Am J Neuroradiol 2001;22:1476-1479
159. Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol 2004;25:210-213
160. Sinha S, Taly AB, Ravishankar S, et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48:613-621
161. Sener RN. Wilson's disease: MRI demonstration of cavitations in basal ganglia and thalami. Pediatr Radiol 1993;23:157
162. Singcharoen T, Chakkaphak K, Udompanich O. Unusual magnetic resonance findings in Wilson's disease. Br J Radiol 1991;64:752-754
163. van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531-536
164. Bakshi R, Ketonen L. MRI of the brain in clinical neurology. In: Joynt RJ, Griggs RC, eds. Baker and Joynt's Clinical Neurology [book on CD-ROM]. Philadelphia, PA: Lippincott Williams & Wilkins; 2001
165. Guillerman RP. The eye-of-the-tiger sign. Radiology 2000;217:895-896
166. Koyama M, Yagishita A. Pantothenate kinase-associated neurodegeneration with increased lentiform nuclei cerebral blood flow. AJNR Am J Neuroradiol 2006;27:212-213
167. Hedera P, Brewer GJ, Fink JK. White matter changes in Wilson disease. Arch Neurol 2002;59:866-867